Image of Dr. Rehemtulla

Alnawaz Rehemtulla, PhD

Professor, Radiation Oncology
Professor, Radiology

NCRC Building 520, Room 1342
1600 Huron Parkway
Ann Arbor, MI. 48109


Administrative Contact


Dr. Rehemtulla has over 25 years of research experience in the field of oncogenic signaling in cancer as well as development and evaluation of inhibitors for these signaling pathways as anticancer therapies. He has developed technologies that enable non-invasive imaging of signaling pathways in cells as well as in mouse models of cancer. These technologies have been leveraged for the discovery of novel drugs that target oncogenic pathways and have antitumor activity. He has also utilized the ability to monitor signaling pathways in live cells to identify previously unappreciated signaling hubs that mediate the transformed phenotype.

Areas of Interest

  • Combining small molecules that inhibit oncogenic pathways with ionizing radiation to improve the efficacy of radiation therapy in brain and pancreatic cancer. Specifically, he is evaluating agents that target the cellular DNA damage response as radiation sensitizers.
  • Signaling pathways that mediate therapeutic resistance in brain tumors.
  • Pathways that enhance the capacity of tumor cells to tolerate radiation therapy by enhancing the capacity to repair damaged DNA are being investigated for therapeutic intervention to restore sensitivity to radiation.


  • MSc, University of Calgary, 1984
  • PhD, University of Calgary, 1987


  • P01 CA085878  (PI: Ross, Leader for Project 2) 07/01/2013 – 06/30/2018,  National Institutes of Health: Brain yumor therapeutic efficacy by quantitative MR, Role: Project 2 Leader.
  • P30 CA046592 (PI: Fearon)   6/01/12 - 5/31/18, National Institutes of Health: University of Michigan Comprehensive Cancer Center Support Grant, Role: Associate Director for Shared Resources.
  • R01 CA155198 (PI: Leopold)  04/01/2012-03/31/2017, National Institutes of Health: Design of MEK inhibitor regimens for the treatment of pancreatic cancer, Role: Co-Investigator
  • R01 CA193690-01 (PI’s: Neamati/Rehemtulla)  06/15/2015-05/31/2020, National Institutes of Health: Efficacy of PDI inhibitors in glioblastoma Goals: Development and evaluation of efficacy of small molecule inhibitors to PDI for the treatment of GBM, Role: Principal Investigator.

Published Articles or Reviews

Selected from 138 publications

  • Bowman BM, Sebolt KA, Hoff BA, Boes JL, Daniels DL, Heist KA, Galbán CJ,Patel RM, Zhang J, Beer DG, Ross BD, Rehemtulla A, Galbán S. Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer. Sci Signal, 8:361, 2015. PMCID: PMC4416214.
  • Nyati S, Schinske-Sebolt K, Pitchiaya S, Chekhovskiy K, Chator A, Chaudhry N, Dosch J, Van Dort ME, Varambally S, Kumar-Sinha C, Nyati MK, Ray D, Walter NG, Yu H, Ross BD, Rehemtulla A. The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signaling. Sci Signal. 8:358. 2015. PMCID:PMC4440544
  • Weber TG, Osl F, Renner A, Pöschinger T, Galbán S, Rehemtulla A, Scheuer W. Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively. Cancer Res, 74(7):1913-23, 2014. PMCID: PMC4269941
  • Nyati S, Schinske K, Ray D, Nyati MK, Ross BD, Rehemtulla A. Molecular imaging of TGFβ-induced Smad2/3 phosphorylation reveals a role for receptor tyrosine kinases in modulating TGFβ signaling. Clin Cancer Res, 17(23):7424-39, 2011. doi: 10.1158/1078-0432.CCR-11-1248. Erratum in: Clin Cancer Res. 18(7):2115, 2012. PMCID: PMC3229686
  • Hamstra DA, Eisbruch A, Naidu MU, Ramana GV, Sunkara P, Campbell KC, Ross BD, Rehemtulla A. Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin Cancer Res,. 16(9):2666-76, 2010. PMID: 20388849

Web Sites